This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks- and Shanghai-based ThousandOaks Biopharmaceuticals , a new contract manufacturing organization fort he biotech industry, said it has received $45M in a Series A financing round. The company's Chairman is Shun Luo, Ph.D.,
ThousandOaks-based agricultural biotech developer Ceres said this morning that its product development programs in Brazil are now being funded in part by that country. Ceres is developing seeds using biotechnology, aimed at energy production. READ MORE>>.
ThousandOaks-based Amgen and venture firm Kleiner Perkins Caufield & Byers have put their backing behind a new, Westlake Village based drug development firm, Atara Biotherapeutics , in an unusual spinout of technology from the biotech giant. Financial details of the funding were not announced.
ThousandOaks-based Xirrus , a developer of Wi-Fi networking hardware, has raised another $20M in funding, according to a regulatory filing from the firm today. Details on the new funding have not yet been announced by the company.
ThousandOaks-based Xirrus confirmed Tuesday that it has raised an additional $20M in funding, bringing the firm's total raised to $80M. Xirrus said the new funding would bolster its reserves, and would go towards partnerships with large integrators. The round was led by InterWest Partners. READ MORE>>.
ThousandOaks-based wireless hardware provider Xirrus has raised yet another $10M in funding, according to a regulatory filing from the company Monday. Details on the funding have not yet been announced by the company. in the funding round, which so far includes 12 investors.
ThousandOaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease.
ThousandOaks-based Ceres , a developer of energy crops for the biofuels energy, has landed $4,989,144 in a grant from the Department of Energy, as part of a $151M effort to fund energy breakthroughs. The effort is targeted at creating feed stocks for biofuels projects, to displace oil and coal.
Xirrus , the wireless hardware provider based in ThousandOaks, has just raised $10.1M in a funding round, part of an ongoing $11.0M funding, according to a regulatory filing by the company. Details on the funding have not yet been announced by the company.
ThousandOaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.
ThousandOaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Source of the new funding was not disclosed. The filing indicates the round came from five investors.
ThousandOaks-based Xirrus , the developer of high speed, high performance wireless networking hardware, has raised another big chunk of financing, saying today that it has raised $23.5M in a Series E funding round. Xirrus said the funding will go towards sales growth and its product.
Amgen Ventures , the venture investment arm of ThousandOaks-based Amgen , is one of the new investors in precision oncology and medicine startup Syapse.
ThousandOaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.
ThousandOaks-based Atara Biotherapeutics announced this morning that it is in a second close of its Series B funding round, bringing its total raised in the funding to $52M. READ MORE>>. amgen lifescience disease renal capital venture biotherapeutics atara'
Amgen Ventures , the venture capital arm of ThousandOaks-based Amgen , has backed the developer of a biopharmaceutical aimed at treating irritable bowel syndrome, kidney disease, and diabetes.
The venture capital arm of ThousandOaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma , which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M
San Diego-based Ocean Aero , a developer of unmanned, autonomous marine vehicles, has scored funding from ThousandOaks-based Teledyne , the companies said this morning. Financial terms of the investment were not disclosed. According to Teledyne, the investment also included a strategic partnership deal.
ThousandOaks-based Ceres , a developer of biofuels crop technology, said Thursday that it has completed a private offering of convertible preferred stock. The funding came from Artal Luxembourg, Ambergate Trust, Gimv, and other undisclosed investors. Ceres is developing improved seed varieties--including.
Amgen Ventures , the venture capital arm of ThousandOaks-based Amgen , is one of the investors in a Boston biotech company, Akili Interactive. Akili is developing digital medicine products aimed at treating cognitive dysfunction, including ADHD, multiple sclerosis, and depression. READ MORE>>.
ThousandOaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics , via its venture capital arm, Amgen Ventures. Lightstone Ventures also participated in the funding. Tizona is based in South San Francisco, and is developing treatments for cancer and autoimmune diseases.
ThousandOaks-based drug development company Atara Biotherapeutics announced this morning that it has added Matthew K. Fust as a board member, and hired Mitchall G. Clark as its Chief Regulatory and Quality Assurance Officer. READ MORE>>. atara biotherapeutics renal disease lifescience amgen executive board'
Whats happening in regions in our counties with startup and entrepreneurial activity, especially in the Conejo Valley (Calabasas to ThousandOaks) is exciting. Many jobs have been created and companies have received funding through our efforts of supporting and bringing value to founders.
a developer of high speed, analog semiconductors, has filed for an IPO, saying late Wednesday evening in a filing with the SEC it is looking to raise up to $115M in an IPO on the NYSE. Inphi is venture backed by Walden International, Tallwood, Mayfield Fund, and Samsung Electronics. In its S-1, the firm said it had net income of $7.3M
ThousandOaks-based Amgen is the lead investor in a round for San Francisco- and Bozeman, Montana-based SiteOne Therapeutics , SiteOne said on Friday. SiteOne said it raised $15M in a Series B funding round, which was led b Amgen, and also included Next Frontier Capital and insiders.
ThousandOaks-based biotech giant a href="[link] said on Monday that it has agreed to acquire its joint venture with Kirin, Kirin-Amgen , in a deal worth $780M. The JV was created in 1984 as a 50-50 joint venture to fund global development of Amgen's EPOGEN, and later included the company's other pharmaceutical products.
ThousandOaks-based biotech giant Amgen is the a new investor in a round for Alector , a developer of immuno-modulatory therapies for Alzheimer's disease and other neurogenerative disorders, which announced a $29.5M funding today. READ MORE>>.
ThousandOaks-based Amgen has returned as one of the investors in cancer therapeutis developer Sutro Biopharma , as part of an $85.4M funding round. in a Series E funding round. Sutro Biopharma is developing a piepline of cancer therapeutics, with the lead contact targeted at treating lymphoma and multiple myeloma.
ThousandOaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. In addition to Amgen, Adheron has received venture capital from Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, and SROne.
ThousandOaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M Akriveia Therapeutics said it is developing immunotherapeutic products that are specifically activated in the microenvironment of the tumor. in a Series A investment. READ MORE>>.
ThousandOaks-based Dantari has raised $47M in its Series A funding, saying that it has launched a new, clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancers and other diseases.
Developers say the ambitious Rice Depot Mercado project will be a mixed-use hub, drawing pedestrian residential traffic from the densely populated area around it. Smith name might ring the loudest bell today for the developer’s various philanthropic efforts. “Bud” Smith , is this year’s only posthumous winner.
—Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.
ThousandOaks-based Teledyne Technologies said today that it has agreed to acquire FLIR Systems, which develops infrared cameras and similar technology, in a deal worth $8.0 Both companies develops sensors, cameras, and sensor systems. Both companies develops sensors, cameras, and sensor systems.
How are you funding this project? This is really also funded because of Mike and my other project, the 101 incubator. The concept of the incubator is we''re raising a fund here locally and ten percent is local the other 90 percent on AngelList, and we''ll be locating here in the town of ThousandOaks.
Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. —More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga.
—Amgen (NASDAQ: AMGN ) of ThousandOaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. Morgan party. The firm has since pledged to help close the gender gap among biotech leadership.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content